These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17708654)

  • 21. A folate receptor-targeted emulsion formulation for paclitaxel.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(6C):4927-31. PubMed ID: 14981947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.
    Kawano K; Onose E; Hattori Y; Maitani Y
    Mol Pharm; 2009; 6(1):98-104. PubMed ID: 19072653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) lipid conjugates as steric barrier molecules in liposomal formulations.
    Ansell SM; Kojic LD; Hankins JS; Sekirov L; Boey A; Lee DK; Bennett AR; Klimuk SK; Harasym TO; Dos Santos N; Semple SC
    Bioconjug Chem; 1999; 10(4):653-66. PubMed ID: 10411464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes.
    Xiang G; Wu J; Lu Y; Liu Z; Lee RJ
    Int J Pharm; 2008 May; 356(1-2):29-36. PubMed ID: 18258394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells.
    Carrion C; de Madariaga MA; Domingo JC
    Life Sci; 2004 Jun; 75(3):313-28. PubMed ID: 15135652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor induction and targeted drug delivery: a new antileukaemia strategy.
    Ratnam M; Hao H; Zheng X; Wang H; Qi H; Lee R; Pan X
    Expert Opin Biol Ther; 2003 Jul; 3(4):563-74. PubMed ID: 12831362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation.
    Stevens PJ; Sekido M; Lee RJ
    Anticancer Res; 2004; 24(1):161-5. PubMed ID: 15015592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted magnetic liposomes loaded with doxorubicin.
    Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
    Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.
    Paulos CM; Reddy JA; Leamon CP; Turk MJ; Low PS
    Mol Pharmacol; 2004 Dec; 66(6):1406-14. PubMed ID: 15371560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery.
    Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
    Biomaterials; 2009 Oct; 30(30):6065-75. PubMed ID: 19674777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
    Pan XQ; Wang H; Lee RJ
    Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy.
    Stephenson SM; Yang W; Stevens PJ; Tjarks W; Barth RF; Lee RJ
    Anticancer Res; 2003; 23(4):3341-5. PubMed ID: 12926073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro release behavior and cytotoxicity of doxorubicin-loaded gold nanoparticles in cancerous cells.
    Asadishad B; Vossoughi M; Alamzadeh I
    Biotechnol Lett; 2010 May; 32(5):649-54. PubMed ID: 20131082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes.
    Pan XQ; Wang H; Lee RJ
    Anticancer Res; 2002; 22(3):1629-33. PubMed ID: 12168846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor.
    Zhao XB; Lee RJ
    Adv Drug Deliv Rev; 2004 Apr; 56(8):1193-204. PubMed ID: 15094215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.